Cigarette smoking and effects on hormone function in premenopausal women.

Cigarette smoke contains compounds that are suspected to cause reproductive damage and possibly affect hormone activity; therefore, we examined hormone metabolite patterns in relation to validated smoking status. We previously conducted a prospective study of women of reproductive age (n = 403) recruited from a large health maintenance organization, who collected urine daily during an average of three to four menstrual cycles. Data on covariates and daily smoking habits were obtained from a baseline interview and daily diary, and smoking status was validated by cotinine assay. Urinary metabolite levels of estrogen and progesterone were measured daily throughout the cycles. For the present study, we measured urinary levels of the pituitary hormone follicle-stimulating hormone (FSH) in a subset of about 300 menstrual cycles, selected by smoking status, with the time of transition between two cycles being of primary interest. Compared with nonsmokers, moderate to heavy smokers ([greater than or equal to] 10 cigarettes/day) had baseline levels (e.g., early follicular phase) of both steroid metabolites that were 25-35% higher, and heavy smokers ([greater than or equal to] 20 cigarettes/day) had lower luteal-phase progesterone metabolite levels. The mean daily urinary FSH levels around the cycle transition were increased at least 30-35% with moderate smoking, even after adjustment. These patterns suggest that chemicals in tobacco smoke alter endocrine function, perhaps at the level of the ovary, which in turn effects release of the pituitary hormones. This endocrine disruption likely contributes to the reported associations of smoking with adverse reproductive outcomes, including menstrual dysfunction, infertility, and earlier menopause. Key words: cigarette smoking, endocrine disruption, estrogen, follicle-stimulating hormone, hormones, menstrual dysfunction, progesterone, steroids, women's health. Environ Health Perspect 113:1285-1290 (2005). doi:10.1289/ehp.7899 available via http://dx.doi.org/[Online 3 June 2005]

**********

Cigarette smoke contains known reproductive toxicants, and smoking has been associated with adverse reproductive outcomes in women such as infertility, subfecundity, younger age at menopause, and menstrual disorders (Department of Health and Human Services 2001). Previously (Windham et al. 1999), we reported that smokers had different menstrual cycle characteristics compared with nonsmokers; heavy smoking was associated with shorter and more variable cycle lengths, with the shortening occurring primarily during the follicular phase. There was some suggestion of increased risk of short luteal phase (< 11 days) and anovulation as well, but the confidence intervals were quite wide. The mechanism of these and other reported effects is not known but may reflect alterations in hormone function by components of tobacco smoke, with smoking suggested as having antiestrogenic effects (Baron et al. 1990). However, studies examining estrogen and its metabolites by smoking status have found somewhat mixed results (Berta et al. 1992; Key et al. 1996; Longcope and Johnston 1988; Zumoff et al. 1990), perhaps partly due to limited sampling points.

Hormone function is difficult to study in non-clinic-based populations because of the cyclical nature of excretion and day-to-day variation in premenopausal women. Under the control of the complex hypothalamic-pituitary-ovarian (HPO) axis, the steroids estrogen and progesterone are released from and reflect ovarian activity and in turn modulate release of gonadotropins from the pituitary via a negative feedback loop. Rising levels of the pituitary hormone follicle-stimulating hormone (FSH) during the luteal to follicular phase transition between menstrual cycles are critical for follicle recruitment and development in the subsequent cycle (van Santbrink et al. 1995). Declining levels during the follicular phase are important for selection of a dominant follicle and its maturation, and FSH peaks again around ovulation. FSH level is considered a marker of ovarian reserve or fertility (Scott et al. 1989; Scott and Hofman 1995) and is elevated among women approaching menopause (Backer et al. 1999; Burger et al. 1995). As such, it may also be useful for identifying ovarian toxicants (Marcus et al. 1993). A few studies have suggested that smokers have higher levels of FSH than do nonsmokers (Backer et al. 1999; Cooper et al. 1995; Cramer et al. 1994). These studies were based on a single serum sample, collected either very early in the cycle or with the cycle timing unknown, and tended to include older women, some of whom were perimenopausal or postmenopausal. Therefore, the purpose of the present study was to examine smoking in relation to the patterns of urinary hormone metabolites throughout the menstrual cycle in premenopausal women to determine whether smoking may exert some of its deleterious effects via an endocrine mechanism. In particular, we were interested in measuring whether estrogen excretion appeared reduced and identifying at what level such an effect may occur by examining the pituitary gonadotropin FSH. Ours is the first study to examine hormone dynamics, with daily metabolite levels of the steroids throughout the cycle and FSH during the luteal-follicular transition, in relation to smoking that was verified by bioassay.

Materials and Methods

The data for this investigation are derived from the Women's Reproductive Health Study, a prospective study of menstrual function and early pregnancy loss conducted among 403 premenopausal women, whose data collection and analytic methods have been described previously (Waller et al. 1998; Windham et al. 1999) and are summarized briefly below. The institutional review boards of both Kaiser Permanente Medical Group and the California Department of Health Services approved the protocol, and participants provided written informed consent.

Women 18-39 years of age enrolled in the Kaiser Permanente Medical Care Program in northern California during 1990-1991 were screened by a short telephone interview to determine eligibility (based on possibility of becoming pregnant) and willingness to collect and freeze first morning urine samples daily for up to 6 months (Waller et M. 1998). About half of those eligible agreed to participate, but some later dropped out (16%) or became ineligible (11%), leaving 403 women who completed urine collection. On average, women collected urine on 92% of appropriate study days during 5.6 menstrual cycles, but because urine collection was not timed to the cycle start dates, a mean of 3.6 complete cycles were collected per woman. Steroid metabolites were measured daily, and FSH was measured in a subset of 300 cycles after additional funding was obtained. Participants completed a detailed baseline telephone interview that asked about demographics, reproductive history, lifestyle factors, and various exposures, including past and current cigarette smoking. Women filled out daily diaries during urine collection, recording vaginal bleeding, intercourse, and contraception, as well as the number of cigarettes smoked each day.

Smoking assessment. The diary was used for determining amount smoked because the daily levels reported provided cycle-specific measures. The average number of cigarettes smoked per day for each cycle was calculated and then categorized; for the FSH subset, we primarily used none, low (1-9 cigarettes/day), and moderate smoking ([greater than or equal to] 10 cigarettes/day). In the full data set with larger numbers, we also delineated a heavy smoking category ([greater than or equal to] 20 cigarettes/day). To validate self-reported smoking, pooled urine samples of 5 days from two to three cycles of each woman were assayed for nicotine and its metabolite cotinine (Elkin et al. 1999; Windham et al. 1999). All of the nonsmokers had urinary cotinine levels < 25 ng/mL, a cut point well within the range used in other studies (Benowitz 1996). Two women who reported less than daily smoking, but with measured corinine levels > 200 ng/mL, were excluded as potential misreporters, as was a nonsmoker who used nicotine gum.

Hormone endpoints. Steroids. The primary estradiol metabolites estrone sulfate and estrone glucuronide [estrone conjugates (EIC)] and the progesterone metabolite pregnanediol-3-glucuronide (PdG) were measured daily by enzyme-linked immunoassays and then adjusted for creatinine concentration, as described previously (Munro et al. 1991; Waller et al. 1998). We determined ovulatory status for each cycle based on a relative rise in progesterone above baseline levels (Kassam et al. 1996; Waller et al. 1998). The day of ovulation (or luteal transition) was estimated using a previously validated algorithm based on the ratio of E1C to PdG during 5-day windows where E1C was declining and PdG was increasing (Baird et al. 1990; Waller et al. 1998; Windham et al. 2002). In a small proportion (5.6%), we reassigned the day of ovulation to better correspond to individual steroid hormone plots. The cycle was divided into the follicular phase (calculated from the first day of menses through the estimated day of ovulation) and the subsequent luteal phase (day after ovulation to day before next menses). Cycle and phase lengths were categorized as short and long based on the 5th and 95th percentiles of their distributions (Windham et al. 1999). For examining and graphing mean daily values of the steroids by smoking status, the cycles were centered at the estimated day of ovulation.

As noted above, urine was collected during many partial cycles, so we generally excluded these, as well as cycles where [greater than or equal to] 30% of days of urine were missing midcycle (~ 700 total). We only examined steroid parameters in the remaining 1,560 cycles for which a day of ovulation was assigned, so we could identify the follicular and luteal phases. Some incomplete first cycles are included in the analyses of luteal-phase measures if there was at least 20 days of urine collection and urine collection started within 14 days of the reported last menstrual period (n = 112). Cycles with incomplete luteal phases (which would include successful pregnancies) were not included in analyses of luteal-phase parameters, but 89 met the inclusion criteria for follicular-phase parameters (including 39 pregnancies). The primary hormone parameters calculated (Windham et al. 2002) for 1,451 follicular phases and 1,459 luteal phases include the following:

* Baseline: the E1C baseline value calculated as the mean over the first 5 days of the cycle. To avoid including elevated "spillover" progesterone values from the previous luteal phase or rising levels of the next, the PdG baseline is the minimum 5-day average occurring before the luteal-phase 5-day maximum.

* Daily average: Mean E1C and PdG levels calculated over the follicular phase or the luteal phase.

* Area under the curve, or "total": the sum of the daily E1C values during the follicular phase or the sum of daily PdG values during the luteal phase.

* Peak: A 3-day average around the maximum E1C or PdG value. For the estrogen metabolite, the maximum value was selected within a 6-day window around the day of ovulation to capture the periovulatory peak. For progesterone, the maximum value during the luteal phase was selected. If values were missing for any of the 3 days, the peak variable was not calculated (18-20% of cycles).

Follicle-stimulating hormone. After procuring additional funding, cycles were selected 2 years later for FSH assay, based on smoking status, to reach a goal of 300 cycles in total. Initially, all cycles of smokers (defined as an average of [greater than or equal to] 1 cigarette reported/day or cotinine > 25 ng/mL) were selected, and two contiguous cycles of nonsmokers (cotinine [less than or equal to] 0.5 ng/mL) were randomly selected, targeting cycles early in urine collection to correspond to the timing of a saliva sample. The FSH assay, based on heat dissociation of the FSH heterodimer and measurement of the FSH [beta]-subunit (Qiu et al. 1998), was conducted blind to smoking status at the University of California, Davis, laboratory where it was developed. Previous studies from the laboratory have shown good correspondence between the circulating FSH heterodimer and the urinary [beta]-subunit (Li et al. 2002). The increase in FSH during the transition between menstrual cycles (e.g., luteal phase of one cycle to follicular phase of the next) is the initiator of events leading to ovulation, so this was identified as the time period of primary interest. FSH was measured in daily samples from 7 days before the first bleed day of a cycle through 17 days afterward to catch the periovulatory rise. Samples were run in duplicate and the average value used, unless the duplicates varied by > 20%, in which case they were rerun. FSH values were also creatinine adjusted. For final analyses, we used only cycles that had adequate specimen remaining to measure FSH during the time period of interest, if there was inadequate sample for nonsmokers, other cycles were substituted, but these were not available for smokers, so the final sample with FSH measures included 112 menstrual cycles among 32 smokers (9 smokers did not have sufficient urine for FSH analyses) and 209 cycles among 93 nonsmoking comparisons.

Because there had been few prior studies examining daily FSH levels, we calculated the daily mean and the slope values for seven different 4-8 day windows of time within the luteal-follicular transition, which were consistent with earlier work from the laboratory (De Souza et al. 1998; Qiu et al. 1997). For FSH analyses, the first bleed day of the cycle was considered day 1 (with no day zero), and we primarily report results for the following windows: days -7 to -1, -5 to 1, -3 to 1, and -3 to 3. For comparison with other studies based on serum FSH, we also examined a basal level as the mean of days 1 to 5. We also examined the maximum FSH value midcycle (periovulatory) and the cycle day on which it occurred (within days 6-17). An FSH parameter was considered missing for a cycle if 25-30% of values within the window were missing (e.g., > 1 day of 4-day windows or 2 days of 7-day windows). This eliminated about 10% of sampling periods.

Statistical analysis. Numerous covariates from the baseline interview were examined as potential confounders, including demographics, reproductive history, body mass index (BMI), and other lifestyle factors (caffeine and alcohol consumption, physical activity). In a previous report, we identified variables associated with the steroid parameters (Windham et al. 2002) and examined these as categorical variables (Table 1) in relation to FSH level and smoking status by analysis of variance. Because the primary analysis is at the cycle level and a woman's cycles are not independent observations, we used mixed models that account for repeated measures for multivariate modeling (Laird and Ware 1982; Zeger and Liang 1986), effectively increasing the standard error of the estimates. Variables identified as potential confounders were included in regression models with each covariate removed one at a time to determine if the association between smoking and a selected FSH parameter (slope or mean of days -5 to 1) changed. If so, that variable was included in final multivariate models. Similar methods were used to build models for examining smoking in relation to steroid levels. In final regression models, we weighted the hormone parameters by the proportion of nonmissing values in the appropriate time frame during each cycle (Windham et al. 2002). Thus, if there were no missing values, the weight was 1, with missing values resulting in down-weighting; mean weights for each parameter ranged from 0.77 to 0.91.

Results

Overall, participants were predominantly white (71%), well educated (40% had a college degree), and parous (88%), with a mean age ([+ or -] SD) of 31 [+ or -] 4.2 years (Waller et al. 1998; Windham et al. 2002). On the baseline questionnaire, 9.2% of women reported being current regular smokers, and the daily diaries indicated that 10% smoked an average of [greater than or equal to] 1 cigarettes/day, with 5% smoking less frequently. Compared with nonsmokers, smokers were significantly less educated, more likely to be of a race other than Asian or white, drank more alcoholic and caffeinated beverages, and were more likely to have had any pregnancy and to have had a pregnancy loss or therapeutic abortion.

The characteristics of the FSH subset are shown in Table 1; smokers did not vary much from those in the overall study except they were even less likely to have a college degree. Nonsmokers in the subset were less likely to be Hispanic (p = 0.04) and more likely to be older (p = 0.10) than were all nonsmokers. The distribution of cycle characteristics (short cycle, long follicular phase, etc.) was similar in the subset and the overall study, and the association of shorter cycle length with smoking was also observed [crude risk ratio = 2.1; 95% confidence interval (CI), 1.1-4.0].

FSH findings. Among nonsmokers, mean FSH levels (for days -5 to 1) tended to be higher in nonwhite, older women with greater caffeine consumption, and levels were lower among women with a history of pregnancy loss and with greater alcohol consumption (Table l). Education, BMI, and other reproductive history variables were not strongly associated with FSH levels. All the mean FSH parameters during the luteal--follicular phase transition were significantly inversely associated with the length of the next cycle and follicular phase, either adjusting for smoking status or among nonsmokers only. The slope parameters that included 5-7 days of the previous cycle were also inversely associated with cycle length.

As shown in Figure 1, the urinary FSH levels reflect the rise during the luteal-follicular transition, with the highest levels occurring early in the follicular phase at days 3-5 and then again around ovulation. Smokers tended to have higher daily FSH levels than nonsmokers during the luteal-follicular phase transition period. Consistent with that, mean FSH parameters in moderate to heavy smokers ([greater than or equal to] 10 cigarettes/day) compared with nonsmokers were statistically significantly increased for all seven of the original time windows (and including the early follicular-phase mean) examined. Light smokers had levels more similar to nonsmokers or very slightly lower. The slopes of FSH during the corresponding periods did not appear to vary consistently by smoking level. Smokers did tend to reach the midcycle peak FSH level > 1 day earlier than did nonsmokers, with an intermediate value among light smokers, but this was less strong after adjustment. One woman had very high FSH levels, which were confirmed on reassay; she was older, a moderate smoker, and a heavy caffeine consumer. She was excluded to determine the degree to which her values were influencing results. This reduced the mean differences between moderate smokers and nonsmokers by about half, so we present these to be conservative in Table 2 showing adjusted differences. Adjustment (for age, race, pregnancy history, BMI, and alcohol and caffeine consumption) changed the magnitude of differences in means only very slightly but increased the estimates for difference in slope parameters among moderate smokers. In general, when including the woman with the high FSH values, the mean FSH levels during the cycle transition were significantly elevated by 52-57% in moderate smokers, whereas excluding her, the means were elevated about 30-35% (Table 2). The effect of excluding her was not consistent for the FSH slope parameters.

Limiting the analyses to only average length cycles (25-35 days) slightly strengthened the elevations in FSH associated with moderate smoking. We examined the smoking level in the previous cycle as well, that is, the one that included the luteal phase of interest, because this would precede FSH measurements. A few cycles drop out because the smoking data are missing, but results were very similar, presumably because smoking habits did not vary greatly across cycles.

Steroid findings. Figure 2, of daily E1C and PdG mean levels, shows the characteristic cyclic patterns of estrogen and progesterone secretion. The steroid metabolites were examined in separate models that included age, race, education, pregnancy history, metabolic equivalence (MET) score (exercise levels), and caffeine consumption. The baseline levels of both steroid hormones were elevated among the heaviest smokers in multivariate models, but not statistically significantly: 22% for E1C and nearly 40% for PdG (Table 3). These elevations were significant at the moderate smoking cut point ([greater than or equal to] 10 cigarettes/day), where there is more power; the mean baseline E1C was elevated > 25% ([beta] = 6.3; 95% CI, 0.40-12.3), and baseline PdG was increased about 35% ([beta] = 0.20; 95% CI, 0.03-0.38), compared with nonsmokers. Progesterone metabolite levels during the luteal phase were somewhat lower among smokers in general (Figure 2B) and consistently about 25% lower among the heaviest smokers (Table 3).

Discussion

The present analysis showed that moderate to heavy smokers had elevated baseline (e.g., early follicular phase) levels of the steroid metabolites and heavy smokers had somewhat dampened progesterone metabolite levels during the luteal phase. Further, we found that mean urinary FSH levels during the time of the luteal-follicular phase transition were higher among moderate to heavy smokers than among nonsmokers. Combined with our previous findings of shorter cycle and follicular-phase lengths among heavy smokers (Windham et al. 1999), an alteration in the endocrine pattern with smoking is indicated.

Because of the nature of its association with various hormonally related diseases, smoking has been considered potentially anti-estrogenic. However, only a few studies have provided metabolic evidence to support this, and these studies are hampered by having few biosampling points, a small number of subjects, or inclusion of postmenopausal women. MacMahon et al (1982) reported reduced urinary excretion of estrone, estradiol, and estriol in the luteal phase among smokers, suggesting that this may be due to reduced estrogen production. Michnovicz et al. (1986) found that smoking induced the 2-hydroxylation of estrone to relatively inactive metabolites and decreased excretion of estriol. However, several studies have not reported differences in serum estradiol concentrations with smoking in premenopausal women (Berta et al. 1992; Key et al. 1996; Longcope and Johnston 1988; Zumoff et al. 1990).

Some of the disease patterns observed with smoking may actually reflect increases in androgens or progesterone. A few studies have reported that smoking increases adrenal activity, with elevations in adrenal androgens seen mostly among postmenopausal smokers (Baron et al. 1995; Friedman et al. 1987; Key et al. 1991; Khaw et al. 1988). Zumoff et al. (1990) measured serum levels at multiple points during the cycle and reported elevated serum progesterone levels during the early follicular phase among smokers, when most progesterone is of adrenocortical origin. This is consistent with our finding of elevated baseline progesterone levels among heavier smokers. However, those authors did not report differences in progesterone levels during the luteal phase. Estrogen was increased in the follicular phase among smokers in that study, which we tended to observe as well. Similar to our finding, Berta et al. (1992) found that regular moderate smokers ([greater than or equal to] 10 cigarettes/day for at least 5 years) had lower plasma progesterone levels on a single sample day during the mid-luteal phase. With an increased baseline PdG reflecting more progesterone of adrenal origin in smokers, the decreased luteal-phase PdG levels we observed may indicate even lower corpus luteum contribution of progesterone to total excretion. Some in vitro studies (Bodis et al. 1992; Gocze et al. 1999; Miceli et al. 2005) have found inhibition of progesterone production by granulosa cells or luteal cells that were treated with cigarette smoke extract or the alkaloids found in smoke (e.g., nicotine, cotinine, anabasine).

The serum FSH level during the first 3-4 days of the cycle is useful clinically to assess fertility and predict success of in vitro fertilization, as well as to identify the peri-menopausal transition (Burger et al. 1995; Mausher et al. 1988; Scott et al. 1989). The few other studies that examined FSH in relation to smoking were based on single serum samples and included women at older ages when FSH may be increasing peri-menopausally. Two studies that measured FSH at the beginning of the cycle found higher levels associated with smoking (Cooper et al. 1995; Cramer et al. 1994), as did a study in which the timing of the serum draw was not known (Backer et al. 1999). These studies support our findings of elevated FSH levels with smoking, but our results expand upon them by examining the dynamics, showing that the elevation in FSH levels among smokers is observable at the end of the prior luteal phase. Furthermore, we observed this effect among reproductive-age women, before onset of the perimenopausal transition.

There are some limitations of the present study that should be considered. Women who comply with the labor-intensive urine collection protocol may not be entirely generalizable, and the eligibility criteria would tend to exclude women with chronic menstrual cycle disturbances. We measured estrone metabolites, which may vary by woman in how well they reflect serum estrogen levels. Furthermore, we cannot establish whether secretion or metabolism is affected by smoking. Our power was somewhat limited for examining FSH levels, because of limited funding and inadequate remaining urine sample for some participants. Thus, for example, we could not examine heavier smoking levels in relation to FSH. We did not examine the effects of passive smoking in this study. The FSH subset should exclude most women exposed to environmental tobacco smoke (ETS) from nonsmokers based on the cotinine level criteria we used (< 0.5 ng/mL), but they would be included in steroid hormone analyses. If ETS causes effects in the same direction as active smoking, but presumably to a lesser extent, this would tend to dilute effects we observed because of ETS exposure being included in the comparison group. Therefore, our results may underestimate the magnitude of the true association with steroid levels.

In conclusion, the present data are consistent with some previously published reports but extend them and present for the first time the effect of smoking on steroid and gonado-tropin patterns across cycles. This approach permits the evaluation of the integrity of the HPO axis during the entire period of follicular recruitment and maturation rather than just analyzing hormone patterns during individual menstrual cycles. Because progesterone modulates FSH in the endocrine feedback loop, the lower progesterone metabolite levels in smokers during the luteal phase are consistent with decreased entrainment of FSH during the luteal-follicular phase transition, leading to the elevations we observed. The shortening of the follicular phase may be a direct consequence of the increased FSH, consistent with other findings (Cramer et al. 1994; De Souza et al. 1998). The increase in FSH may accelerate the recruitment and development of follicles, moving ovulation earlier. Short follicular phase has been associated with decreased fecundity or in vitro fertilization rates in several studies (Check et al. 1992; Fukuda et al. 2001; Kolstad et al. 1999; Liss et al. 2002). Shorter follicular phase may result in inadequate follicle development, followed by inadequate corpus luteum function. Because progesterone controls endometrial response, it is critical for early pregnancy maintenance; luteal-phase deficiency or decreased progesterone has been implicated as a cause of infertility and fetal loss (Pittaway et al. 1983; Tulppala et al. 1991; Wuttke et al. 2001). This pattern of higher FSH levels and shorter cycles in smokers is also consistent with the observation that smokers tend to experience earlier menopause (Cooper et al. 1999; Midgette and Baron 1990). Thus, the decreased progesterone and perturbation of FSH suggest both a target and one mechanism by which cigarette smoke may alter ovarian function and reduce female fertility. Because cigarette smoke contains thousands of chemicals, this pathway may serve as a model for some endocrine effects of other environmental exposures.

REFERENCES

Backer LC, Rubin CS, Marcus M, Kieszak SM, Schober SE. 1999. Serum follicle-stimulating hormone and luteinizing hormone levels in women aged 35-60 in the U.S. population: the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994). Menopause 6:29-35.

Baird DD, Weinberg CR, Wilcox A J, McConnaughey DR, Musey PI. 1990. Using the ratio of urinary estrogen and progesterone metabolites to estimate day of ovulation. Stat Med 10:255-269.

Baron JA, Comi RJ, Cryns V, Brinck-Johnsen T, Mercer NG. 1995. The effects of cigarette smoking on adrenal cortical hormones. J Pharmacol Exp Thor 272:151 155.

Baron JA, La Vecchia C, Levi F. 1990. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol 167:502 514.

Benowitz NL. 1996. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev 18:188-204.

Berta L, Frairia R, Fortunati N, Fazzari A, Gaidano G. 1992. Smoking effects on the hormonal balance of fertile women. Horm Res 37:45-48.

Bodis J, Hanf V, Torok A, Tinneberg HR. 1992. Smoking and corpus luteum function [Letter]. Fertil Steril 57:703.

Burger HG, Dudley ED, Hopper JL, Shelley JM, Green A, Smith A, et al. 1995. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab 80:3537-3545.

Check JH, Adelson H, Lurie D, Jamison T. 1992. Effect of the short follicular phase on subsequent conception. Gynecol Obstet Invest 34:186-183.

Cooper GS, Baird DD, Hulka BS, Weinberg CR, Savitz DA, Hughes C. 1995. Follicle-stimulating hormone concentrations in relation to active and passive smoking. Obstet Gyneco185:407-411.

Cooper GS, Sandier DP, Bohlig M. 1999. Active and passive smoking and the occurrence of natural menopause. Epidemiology 10:771-773.

Cramer DW, Barbieri RL, Xu H, Reichardt JKV. 1994. Determinants of basal follicle-stimulating hormone levels in pre-menopausal women. J Clin Endocrinol Metab 79:1105-1109.

De Souza MJ, Miller BE, Loucks AB, Luciano AA, Pescatello LS, Campbell CG, et al. 1998. High frequency of luteal phase deficiency and anovulation in recreational women runners: blunted elevation in follicle-stimulating hormone observed during luteal-follicular transition. J Clin Endocrinol Metab 83:4220-4232.

Department of Health and Human Services. 2001. Women and Smoking: A Report of the Surgeon General. Washington, DC:U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General.

Elkin EP, Windham GC, Benowitz NL, Swan SH. 1999. Occasional smoking in a study of premenopausal women. Am J Public Health 89:420-421.

Friedman AJ, Ravnikar VA, Barbieri RL. 1987. Serum steroid hormone profiles in postmenopausal smokers and nonsmokers. Fertil Steril 47:398-401.

Fukuda M, Fukuda K, Andersen CY, Byskov AG. 2001. Characteristics of human ovulation in natural cycles correlated with age and achievement of pregnancy. Human Reprod 16:2501-2507.

Gocze PM, Szabo I, Freeman DA. 1999. Influence of nicotine, cotinine, anabasine and cigarette smoke extract on human granulosa cell progesterone and estradiol synthesis. Gynecol Endocrinol 13:266-272.

Kassam A, Overstreet JW, Snow-Harter C, De Souza MJ, Gold EB, Lasley BL. 1996. Identification of anovulation and transient luteal function using a urinary pregnanediol-3-glucuronide ratio algorithm. Environ Health Perspect 104:408-413.

Key TJA, Pike MC, Baron JA, Moore JW, Wang DY, Thomas BS, et al. 1991. Cigarette smoking and steroid hormones in women. J Steroid Biochem Mol Biol 39:529-534.

Key TJA, Pike MC, Brown JB, Hermon C, Allen DS, Wang DY. 1996. Cigarette smoking and urinary oestrogen excretion in premenopausal and post-menopausal women. Br J Cancer 74:1313-1316.

Khaw K-T, Chir MBB, Tazuke S, Barrett-Conner E. 1988. Cigarette smoking and levels of adrenal androgens in postmenopausal women. N Engl J Med 318:1705-1709.

Kolstad HA, Bonde JP, Hjollund NH, Jensen TK, Henriksen TB, Ernst E, et al. 1999. Menstrual cycle pattern and fertility: a prospective follow-up study of pregnancy and early embryonal loss in 295 couples who were planning their first pregnancy. Fertil Steril 71:490-496.

Laird N, Ware J. 1982, Random effects models for longitudinal data, Biometrics 38:963-974.

Li H, Chen J, Todd H, Nakajima ST, Overstreet JW, Lasley BL. 2002. The use of urinary FSH beta to identify the day of ovulation. Fertil Steril 77(5):961-966.

Liss JR, Check JH, Shucoski K, Check ML. 2002. Effect of short follicular phase on conception outcome. Forth Steril 77(suppl 3):S17.

Longcope C, Johnston CC. 1988. Androgen and estrogen dynamics in pro- and postmenopausal women: a comparison between smokers and nonsmokers. J Clin Endocrinol Metab 67:379-383.

MacMahon B, Trichopoulos D, Cole P, Brown J. 1982. Cigarette smoking and urinary estrogens. N Engl J Med 307:1062-1065.

Marcus M, Grunfeld L, Berkowitz G, Kaplan P, Godbold J. 1993. Urinary follicle-stimulating hormone as a biological marker of ovarian toxicity. Forth Steril 59:931-932.

Mausher SJ, Oehninger S, Simonetti S, Matta J, Ellis LM, Liu H-C, et el. 1988, The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. Fertil Steril 50:298-307.

Miceli F, Minici F, Tropea A, Catino S, Orlando M, Lamanna G, et al. 2005. Effects of nicotine on human lutea cells in vitro: a possible role on reproductive outcome for smoking women. Biol Reprod 72:628-632.

Michnovicz JJ, Herschcopf RJ, Naganuma H, Bradlow HL, Fishman J. 1986. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med 315:1305-1309.

Midgette AS, Baron JA. 1990. Cigarette smoking and the risk of natural menopause. Epidemiology 1:474-480.

Munro CJ, Stabenfeldt GH, Cragun JR, Addiego LA. 1991. Relationship of serum estradiol and progesterone concentrations to the excretion profiles of their major urinary metabolites as measured by enzyme immunoassay and radioimmunoassay. Clin Chem 37:838-844.

Pittaway DE, Maxson W, Daniell J, Herbert C, Wentz AC. 1983. Luteal phase defects in infertility patients with endometriosis. Fertil Steril 39:712-713.

Qiu Q, Kuo A, Todd HE, Bias JA, Gould JE, Overstreet JW, et al. 1998. Enzyme-immunoassay method for the beta subunit of urinary follicle stimulating hormone (FSH) and its application for measurement of total urinary FSH. Fertil Steril 69:278-285.

Qiu Q, Overstreet JW, Todd H, Nakajima ST, Stewart DR, Lasley BL. 1997. Total urinary follicle stimulating hormone as a biomarker for detection of early pregnancy and peri-implantation spontaneous abortion. Environ Health Perspect 105:862-866.

Scott RT, Herman GE. 1995. Prognostic assessment of ovarian reserve, Fertil Steril 63:1-11.

Scott RT, Toner JP, Muasher SH, Oehninger S, Robinson S, Rosenwaks Z. 1989. Follicle-stimulation hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 51:651-654.

Tulppala M, Bjorses U-M, Stenman U-H, Wahlstrom T, Ylikorkala O. 1991. Luteal phase defect in habitual abortion: progesterone in saliva. Fertil Steril 56:41-44.

van Santbrink EJP, de Jong FH, Hop WC, Fauser BCJM, van Dessel TJHM. 1995. Decremental follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle. Fertil Steril 64:37-43.

Waller K, Swan SH, Windham GC, Fenster L, Elkin EP, Lasley BL. 1998. Use of urine biomarkers to evaluate menstrual function in healthy premenopausal women, Am J Epidemiol 147:1071-1080.

Windham GC, Elkin E, Fenster L, Waller K, Anderson M, Mitchell PR, et al. 2002. Ovarian hormones in premenopausal women: variation by demographic, reproductive and menstrual cycle characteristics. Epidemiology 13:675-684.

Windham GC, Elkin EP, Swan SH, Waller KO, Fenster L. 1999. Cigarette smoking and effects on menstrual function. 0bstet Gynecol 93:59-65.

Wuttke W, Ptizel L, Seidlova-Wutkke, Hinney B. 2601. LH pulses and the corpus luteum: the luteal phase deficiency (LPD). Vitam Herin 63:131-158.

Zeger S, Liang KY. 1986. Longitudinal data analysis for discrete and continuous outcomes, Biometrics 42:121-130.

Zumoff B, Mill L, Levit CD, Miller EH, Heinz U, Kalin M, et al. 1990. The effect of smoking on serum progesterone, estradiol, and luteinizing hormone levels over a menstrual cycle in normal women. Steroids 55:507-511.

Gayle C. Windham, (1) Patrick Mitchell, (2) Meredith Anderson, (3) and Bill L. Lasley (4)

(1) Division of Environmental and Occupational Disease Control, California Department of Health Services, Oakland, California, USA; (2) California Department of Health Services, Sacramento, California, USA; (3) Impact Assessment Inc., La Jolla, California, USA; (4) Institute of Toxicology and Environmental Health, School of Medicine, University of California, Davis, California, USA

Address correspondence to G.C. Windham, California Department of Health Services, Environmental Health Investigations Branch, 850 Marina Bay Parkway, Building P, Richmond, CA 94804 USA. Telephone: [phone]. Fax: [phone]. E-mail: [e-mail]

We thank the staff at Kaiser DOR and the California Department of Health Services, especially S. Swan, L. Fenster, and K. Waller for contributions to the original study; we also thank E. Elkin for initial analyses. Cotinine was measured at the laboratory of N. Benowitz, University of California San Francisco.

This work was supported by Tobacco-Related Disease Research Program grants 7RT-0119 and 3RT-0093, and the California Department of Health Services.

The authors declare they have no competing financial interests.

Received 31 December 2004; accepted 2 June 2005.

Table 1. Participant characteristics and mean FSH level in FSH subset,
by smoking status.

                                            Nonsmokers

                                                     FSH
                                   No. of      (mean [+ or -] SD)
Variable                          women (%)          (a)

Race *
  White                            72 (77.4)   0.36 [+ or -] 0.17
  Asian                            15 (16.1)   0.51 [+ or -] 0.35
  Other                             6 (6.5)    0.48 [+ or -] 0.20
Age (years)
  < 30                             26 (27.9)   0.33 [+ or -] 0.22
  30-34                            34 (36.6)   0.42 [+ or -] 0.20
  [greater than or equal to] 35    33 (35.5)   0.42 [+ or -] 0.22
Pregnancy history
  0 pregnancies                     7 (7.5)    0.49 [+ or -] 0.38
  [greater than or equal to] 1
    pregnancy, 0 losses            59 (63.4)   0.41 [+ or -] 0.22
  [greater than or equal to] 1
    pregnancy, [greater than or
    equal to] 1 loss               27 (29.0)   0.34 [+ or -] 0.15
Education *
  No college                       21 (22.6)   0.44 [+ or -] 0.23
  Some college                     29 (31.2)   0.38 [+ or -] 0.16
  College graduate                 43 (46.2)   0.38 [+ or -] 0.25
BMI (kg/[m.sup.2])
  < 19.1                            6 (6.5)    0.47 [+ or -] 0.44
  19.1-27.3                        66 (71.0)   0.39 [+ or -] 0.21
  > 27.3                           21 (22.6)   0.38 [+ or -] 0.18
MET score
  0                                42 (45.2)   0.43 [+ or -] 0.26
  > 0 to < 40                      37 (39.8)   0.36 [+ or -] 0.19
  [greater than or equal to] 40    14 (15.0)   0.37 [+ or -] 0.16
Caffeine (mg/day) *
  0                                35 (37.6)   0.35 [+ or -] 0.23
  < 300                            48 (51.6)   0.41 [+ or -] 0.21
  [greater than or equal to] 300   10 (10.8)   0.48 [+ or -] 0.21
Alcohol * (drinks/week)
  0                                26 (28.0)   0.45 [+ or -] 0.29
  1-3                              64 (68.8)   0.38 [+ or -] 0.19
  [greater than or equal to] 4      3 (3.2)    0.29 [+ or -] 0.09

                                              Smokers

                                                     FSH
                                    No. of     (mean [+ or -] SD)
Variable                           women (%)         (a)

Race *
  White                            24 (75.0)   0.50 [+ or -] 0.48
  Asian                             2 (6.3)    0.90 [+ or -] 0.50
  Other                             6 (18.8)   0.32 [+ or -] 0.14
Age (years)
  < 30                             12 (37.5)   0.36 [+ or -] 0.14
  30-34                            12 (37.5)   0.40 [+ or -] 0.21
  [greater than or equal to] 35     8 (25.0)   0.81 [+ or -] 0.74
Pregnancy history
  0 pregnancies                     1 (3.1)    0.46 [+ or -] 0.21
  [greater than or equal to] 1     20 (62.5)   0.52 [+ or -] 0.55
    pregnancy, 0 losses
  [greater than or equal to] 1     11 (34.4)   0.45 [+ or -] 0.22
    pregnancy, [greater than or
    equal to] 1 loss
Education *
  No college                       16 (50.0)   0.55 [+ or -] 0.62
  Some college                     13 (40.6)   0.43 [+ or -] 0.22
  College graduate                  3 (9.4)    0.53 [+ or -] 0.14
BMI (kg/[m.sup.2])
  < 19.1                            2 (6.3)    0.29 [+ or -] 0.08
  19.1-27.3                        19 (59.4)   0.58 [+ or -] 0.54
  > 27.3                           11 (34.4)   0.41 [+ or -] 0.31
MET score
  0                                10 (31.2)   0.45 [+ or -] 0.25
  > 0 to < 40                      16 (50.0)   0.55 [+ or -] 0.63
  [greater than or equal to] 40     6 (18.8)   0.45 [+ or -] 0.21
Caffeine (mg/day) *
  0                                 3 (31.2)   0.39 [+ or -] 0.19
  < 300                            19 (59.4)   0.44 [+ or -] 0.22
  [greater than or equal to] 300   10 (31.2)   0.63 [+ or -] 0.76
Alcohol * (drinks/week)
  0                                 5 (15.6)   0.64 [+ or -] 0.91
  1-3                              17 (53.1)   0.41 [+ or -] 0.18
  [greater than or equal to] 4     10 (31.3)   0.55 [+ or -] 0.37

MET, metabolic equivalence.

(a) Mean FSH for days -5 to 1 calculated for cycles (vs. woman
basis). Data from Women's Reproductive Health Study, California
Department of Health Services. * p < 0.05 for test of independence
between smoking status and covariate.

Table 2. Adjusted (a) difference in FSH metabolic parameters by
smoking level and 95% Cls.

                               Cigarettes/day (b)

Parameter and     None (n= 186)    [less than or equal to] (n = 49)
cycle days (c)      Intercept               [beta] (95% Cl)

FSH slope
  -7 to -1            0.02              -0.02 (-0.04 to 0.00)
  -5 to 1             0.04              -0.02 (-0.05 to 0.01)
  -3 to 1             0.09              -0.04 (-0.10 to 0.01)
Mean daily FSH
  -7 to -1            0.31              -0.03 (-0.12 to 0.06)
  -5 to 1             0.37              -0.06 (-0.17 to 0.05)
  -3 to 1             0.40              -0.08 (-0.21 to 0.04)
  -3 to 3             0.50              -0.08 (-0.22 to 0.06)
  1 to 5              0.68              -0.09 (-0.29 to 0.10)

                          Cigarettes/day (b)

Parameter and     [greater than or equal to] (n = 48)
cycle days (c)            [beta] (95% Cl)

FSH slope
  -7 to -1              0.02 (-0.003 to 0.04)
  -5 to 1               0.02 (-0.015 to 0.06)
  -3 to 1               0.02 (-0.04 to 0.07)
Mean daily FSH
  -7 to -1              0.09 (-0.01 to 0.20)
  -5 to 1               0.12 10.00 to 0.24)
  -3 to 1               0.14 (0.003 to 0.28)
  -3 to 3               0.10 (-0.06 to 0.26)
  1 to 5                0.006 (-0.22 to 0.23)

(a) Adjusted for age, race, pregnancy history, BMI, and alcohol and
caffeine consumption in mixed models for repeated measures, with
weighting of FSH parameter by proportion of nonmissing within the
window. (b) Smoking as reported during cycle starting with day 1; n
is for the parameter with the largest numbers. These vary by a few
cycles because of missing data; one outlier was excluded. (c) Days
are counted with first bleed day of a cycle numbered as day 1. Data
from Women's Reproductive Health Study, California Department of
Health Services.

Table 3. Adjusted (a) difference and 95% Cls in steroid hormone
metabolite parameters by smoking level.

                                      Cigarettes/day

                                                [less than or
                              None (n (b)         equal to]
                                = 1,313)        19 (n = 117)
Hormone parameter              Intercept       [beta] (95% Cl)

Estrogen (ng/mg creatinine)
  Baseline                        24.9        3.9 (0.06 to 7.6)
  Total FP                       584.6        6.8 (-66.8 to 80.3)
  Daily average FP                39.0        1.2 (-3.1 to 5.5)
  Peak to periovulatory           70.4       -0.3 (-10.0 to 9.4)
Progesterone ([micro]g/mg
  creatinine)
  Baseline                         0.54      -0.03 (-0.14 to 0.08)
  Total LP                        56.7       -1.7 (-9.4 to 5.9)
  Daily average LP                 4.66      -0.17 (-0.80 to 0.47)
  Peak LP                          6.64      -0.36 (-1.35 to 0.63)

                                 Cigarettes/day

                                  [less than or
                                    equal to]
                                    19 (n = 117)
Hormone parameter                [beta] (95% Cl)

Estrogen (ng/mg creatinine)
  Baseline                      5.7 (-3.5 to 14.8)
  Total FP                     29.1 (-159.6 to 217.8)
  Daily average FP              4.3 (-6.3 to 14.9)
  Peak to periovulatory       -11.5 (-32.7 to 9.7)
Progesterone ([micro]g/mg
  creatinine)
  Baseline                      0.21 (-0.04 to 0.47)
  Total LP                    -15.5 (-32.2 to 1.1)
  Daily average LP            -1.34 (-2.72 to 0.04)
  Peak LP                     -1.63 (-3.65 to 0.40)

Abbreviations: FP, follicular phase; LP, luteal phase.

(a) Adjusted for age, race, education, prior pregnancies, caffeine,
and MET score (exercise level). (b) n indicates the parameter
with the largest numbers (e.g., follicular-phase estrogen and
luteal-phase progesterone); others vary because of missing
data, with peaks having smaller n values by 260-300 cycles
overall. Data from Women's Reproductive Health Study,
California Department of Health Services.